期刊
LEUKEMIA RESEARCH
卷 36, 期 -, 页码 S27-S34出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/S0145-2126(12)70006-1
关键词
Continuous treatment; Duration of therapy; Long-term treatment; Multiple myeloma; Novel agents; Relapsed/refractory; Re-treatment
资金
- Celgene Corporation
- Ortho Biotech
- Mundipharma
- Janssen
- Onyx
Novel agents such as thalidomide, bortezomib, and lenalidomide have improved outcomes and extended survival in patients with relapsed and/or refractory multiple myeloma (RRMM). These agents appear to be most effective when used at first relapse rather than later in the treatment sequence; however, the optimal duration of therapy has not been defined. Continuous therapy from relapse to disease progression may be able to maintain suppression of residual disease, thereby extending overall survival. This article reviews the currently available data on treatments, including novel agents for patients with RRMM, focusing on the duration of therapy required to improve clinical outcomes. (c) 2012 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据